Rocket Pharmaceuticals Announces Two Presentations at the European Society for Immunodeficiencies 2020 Meeting – Business Wire

NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces two presentations at the European Society for Immunodeficiencies (ESID) 2020 Meeting to be held virtually October 14-17, 2020. An oral presentation will provide an update on data from the Phase 1/2 clinical trial of RP-L201 for Leukocyte Adhesion Deficiency-I (LAD-I). An e-poster will highlight preclinical study data on RP-L401 for Infantile Malignant Osteopetrosis (IMO).

Additional presentation details can be found below:

Oral Presentation

Title: A Phase 1/2 Study of Lentiviral-Mediated Ex-Vivo Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I): Results from Phase 1 Session Title: Treatment Presenter: Donald B. Kohn, M.D., Professor of Microbiology, Immunology and Molecular Genetics, Pediatrics (Hematology/Oncology), Molecular and Medical Pharmacology, and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California, Los Angeles Session Date: Friday, October 16, 2020 Session Time: 10:45 a.m. 12:01 p.m. CEST Lecture Time: 11:45 a.m. CEST Location: Hall D

This session will be followed by a Q&A from 12:01 p.m. to 12:30 p.m. CEST

E-Poster

Title: Preclinical Efficacy and Safety of EFS.HTCIRG1-LV Supports IMO Gene Therapy Clinical Trial Initiation Presenter: Ilana Moscatelli, Ph.D., Associate Researcher, Division of Molecular Medicine and Gene Therapy, Lund University, Sweden

About Leukocyte Adhesion Deficiency-I

Severe Leukocyte Adhesion Deficiency-I (LAD-I) is a rare, autosomal recessive pediatric disease caused by mutations in the ITGB2 gene encoding for the beta-2 integrin component CD18. CD18 is a key protein that facilitates leukocyte adhesion and extravasation from blood vessels to combat infections. As a result, children with severe LAD-I (less than 2% normal expression) are often affected immediately after birth. During infancy, they suffer from recurrent life-threatening bacterial and fungal infections that respond poorly to antibiotics and require frequent hospitalizations. Children who survive infancy experience recurrent severe infections including pneumonia, gingival ulcers, necrotic skin ulcers, and septicemia. Without a successful bone marrow transplant, mortality in patients with severe LAD-I is 60-75% prior to the age of 2 and survival beyond the age of 5 is uncommon. There is a high unmet medical need for patients with severe LAD-I.

Rockets LAD-I research is made possible by a grant from the California Institute for Regenerative Medicine (Grant Number CLIN2-11480). The contents of this press release are solely the responsibility of Rocket and do not necessarily represent the official views of CIRM or any other Agency of the State of California.

About Infantile Malignant Osteopetrosis

Infantile Malignant Osteopetrosis (IMO) is a rare, severe autosomal recessive disorder caused by mutations in the TCIRG1 gene, which is critical for the process of bone resorption. Mutations in TCIRG1 interfere with the function of osteoclasts, cells which are essential for normal bone remodeling and growth, leading to skeletal malformations, including fractures and cranial deformities which cause neurologic abnormalities including vision and hearing loss. Patients often have endocrine abnormalities and progressive, frequently fatal bone marrow failure. As a result, death is common within the first decade of life. IMO has an estimated incidence of 1 in 200,000. The only treatment option currently available for IMO is an allogenic bone marrow transplant (HSCT), which allows for the restoration of bone resorption by donor-derived osteoclasts which originate from hematopoietic cells. Long-term survival rates are lower in IMO than those associated with HSCT for many other non-malignant hematologic disorders; severe HSCT-related complications are frequent. There is an urgent need for additional treatment options.

RP-L401 was in-licensed from Lund University and Medizinische Hochschule Hannover.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The companys platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rockets first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. For more information about Rocket, please visit http://www.rocketpharma.com.

Rocket Cautionary Statement Regarding Forward-Looking Statements

Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding its guidance for 2020 in light of COVID-19, the safety, effectiveness and timing of product candidates that Rocket may develop, to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Infantile Malignant Osteopetrosis (IMO) and Danon Disease, and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket's ability to monitor the impact of COVID-19 on its business operations and take steps to ensure the safety of patients, families and employees, the interest from patients and families for participation in each of Rockets ongoing trials, our expectations regarding when clinical trial sites will resume normal business operations, our expectations regarding the delays and impact of COVID-19 on clinical sites, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket's dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket's Annual Report on Form 10-Q for the quarter ended June 30, 2020, filed August 5, 2020 with the SEC. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Follow this link:
Rocket Pharmaceuticals Announces Two Presentations at the European Society for Immunodeficiencies 2020 Meeting - Business Wire

CA Prop 14: Stem cell research – CBS News 8

Proposition 14 is on the California ballot to continue funding stem cell research by borrowing up to $5.5 billion through bonds.

CALIFORNIA, USA California Proposition 14 is a vote to approve $5.5 billion dollars for stem cell research and research facilities in the state. In 2004, California voters approved Proposition 71. It gave legal protection to stem cell research that was hoping to find new medical treatments or cures for everything from Parkinsons to cancer. Proposition 71 also approved spending more than $3 billion to use for stem cell research and to build research facilities. Since 2004, most of the funding has been spent.

Proposition 14 would help to continue the funding of the existing research program with an additional $5.5 billion. The total estimated cost of the bond is an additional $260 million per year for the next 30 years. The total cost to pay off the bond is estimated to be $7.8 billion ($5.5 billion in bonds + $2.3 billion in interest).

Proposition 14 does offer a chance for the state to make back some money, a unique property compared to most state bonds. If the research leads to new inventions that earn revenue, the state will get a portion of the profits.

So far thats only raised about $350,000 or about 0.01% of the bond money weve already spent on stem cell work since 2004.

Find more background about this proposition as well as opinions from both sides on the California Voter Guide or on your local voter guide.

The California Stem Cell Research, Treatments, and Cures Initiative of 2020

A yes vote approves $5.5 billion dollars for stem cell research and research facilities. The money will come from a bond.

A no vote means that the states existing stem cell program would start to wind down.

Read more:
CA Prop 14: Stem cell research - CBS News 8

Guide to California’s Propositions on the 2020 Ballot – monroviaweekly

With the election date getting closer, it is important that Californians know what they are being asked to vote on. File photo by Terry Miller / Beacon Media News

By Destiny Torres

This years general election is right around the corner. As Nov. 3 grows nearer, voters must understand everything that will appear on their ballots.

There will be a total of 12 propositions for Californians to vote on this year. While it may be difficult to research all of them on ones own, these are all the ballot initiatives voters will be asked to decide on this election.

With this proposition, voters will be deciding on whether or not to issue $5.5 billion in state bonds to the California Institute for Regenerative Medicine (CIRM).

CIRM was created in 2004 after voters approved Proposition 71, the California Stem Cell and Research Initiative, to fund stem cell research along with issuing $3 billion in bonds. Proposition 71 also created a 29-member governing board to oversee the program; Proposition 14 would increase the number of members to 35.

Approving this initiative would increase state costs possibly over the next 30 years.

The approval of this measure would mean amending the states constitution to require that commercial and industrial properties be taxed according to market value rather than on the purchase price. Exempted from these changes are residential properties, agricultural land and owners of commercial and industrial properties whose value is less than $3 million.

Those opposed argue that the measure would repeal taxpayer protections provided by Proposition 13, an initiative approved in 1978 that stabilized state property taxes by capping it at a 2% increase per year.

But, as bad as that would be for the economy overall, split roll takes special aim at agriculture and would sweep across our farms and ranches like a wildfire, wrote Ted Gaines, a former state senator and member of the California State Board of Equalization wrote for Bakersfield.com.

Proposition 15 only applies to commercial and industrial properties, or holdings worth over $3 million.

Those who approve argue that larger companies should not be taxed the same way that homeowners or smaller businesses do.

Were asking for companies like Disneyland or Universal Studios that make huge amounts of money to pay property taxes based on fair market valuethe same thing that homeowners and, frankly, most businesses have to do, Josh Pechthalt, president of the California Federation of Teachers, told Rewire News Group.

The money from these new taxes would be dispersed in a very specific way rather than going to one general fund. The ballot initiative states that revenue from the new taxations would go to public schools, community colleges and local governments.

Proposition 209, or the Affirmative Action Initiative, is a measure approved in 1996 which amended the state constitution to prohibit public state institutions from considering race, sex, or ethnicity in areas of public employment, public education and public contracting, therefore banning the use of affirmative action.

Affirmative action is the practice of favoring individuals in certain groups that are known to have been historically discriminated against. It was used to ensure that minority groups had more access to public employment and schooling.

Proposition 16 would defeat Proposition 209. If approved, state and local governments, public schools and other public services would be allowed to use affirmative action policies that would grant access to people based on their race, sex and ethnicity.

Currently, the states constitution disqualifies people with felonies from voting until both their prison sentence and parole are completed.

Proposition 17 would amend that law by allowing people with felonies who have completed their prison sentence to vote while on parole.

A yes vote for this initiative would make it possible for 17-year-olds to vote in primary elections if they will be turning 18 by the time of the general election.

This ballot initiative targets the taxes of homeowners who are 55 or older, people with disabilities, or people who lost their homes to a natural disaster.

A yes vote on Proposition 19 would amend the states constitution to allow these homeowners to transfer their lower property taxes to their newer home if they choose to buy somewhere else in the state regardless of its market value, giving them a major tax break.

It also means that if someone were to inherit their home from a family member and later try to rent it out to Airbnb instead of using it as their primary home, they would receive a tax increase based on the homes present market value.

Additional money made from this value would go to firefighters and public schools.

A no vote means the law remains the same and property tax transfers can only occur if the market value is the same or higher of their previous home.

Proposition 20 would change many laws passed to reduce the states prison population.

Crimes like theft and fraud are currently charged as misdemeanors, Proposition 20 would change that so they are charged as felonies.

It would also make parole review boards look at other factors when determining whether or not non-violent felons should receive parole. These new elements would include age, skills and mental condition.

Along with these changes, the proposition would also require that convicted felons submit their DNA to the state and federal government databases.

A vote yes would increase the jail population leading to an estimated major increase in the states costs.

This proposition would allow local governments to establish rent control on properties that are over 15 years old.

If Proposition 22 were to be approved, drivers who work for apps like Uber, DoorDash and Lyft would be labeled as independent contractors. These app companies would then implement their own labor and wage policies, and not have to adhere to state labor laws such as providing minimum wage, unemployment insurance and workers compensation.

If the proposition is rejected, the government would be able to decide whether drivers are independent contractors or employees.

This proposition would require at least one licensed physician to be present at the clinic at all times unless there is a significant staff shortage. Without state approval, clinics would not be allowed to close or reduce services. Proposition 23 also prohibits clinicians to refuse care to patients based on their form of payment.

It would also require clinics to report newfound data to the state and the federal government.

With the digital age in full swing, many consumers have become worried about what businesses do with their private information like using it for marketing or advertising.

Proposition 24 would further protect consumers information by ensuring that businesses do not share private information upon the request of a consumer and giving people the ability to opt-out.

It also adds more protection for younger users like businesses would need to get permission before collecting information from people under 16 or gain permission from parents before collecting data from children under 13.

If a business were to violate any rules, this proposition also changes the possibility of businesses fixing their mistake before paying the price for it.

In California, a person who is arrested has the option of paying their bail or taking out a bail loan. Because of this, wealthier people can get out of jail right away without borrowing money or taking a plea deal.

This proposition would replace the cash bail system with an algorithm that would determine a criminals flight risk before their trial.

Read the rest here:
Guide to California's Propositions on the 2020 Ballot - monroviaweekly

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Development Trends & Competitive Analysis by Leading Industry Players – The…

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market is expected to exceed more than US$ 4.5 Billion by 2024 at a CAGR of 4% in the given forecast period.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the GE Healthcare, A&D Medical, Dragerwerk, Hill-Rom, and Philips Healthcare. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

You Can Find Full Report: https://www.marketresearchengine.com/autologous-stem-cell-and-non-stem-cell-based-therapies-market

Autologous stem-cell transplantation (also called autogenetic, autogenic, or autogenic stem-cell transplantation or auto-SCT) is that the autologous transplantation of stem cellswhich is, the uniform cells or stem cells (cells from which different styles of cells develop) area unit taken from someone, accumulated, and given back to an equivalent person later. Although its most frequently dead by means that of hematogenic vegetative cells (antecedent of cells that forms blood) in hematogenic stem cell transplantation, in some cases internal organ cells square measure used profitably to mend the damages because of heart attacks.

The scope of the report includes a detailed study of global and regional markets for Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market with the reasons given for variations in the growth of the industry in certain regions.

Reasons to Buy this Report:

1) Obtain the most up to date information available on all Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market

2) Identify growth segments and opportunities in the industry. 3) Facilitate decision making on the basis of strong historic and forecast Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market.

4) Assess your competitors refining portfolio and its evolution.

The major driving factors of Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market are as follows:

The restraining factors of Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market are as follows:

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market has been segmented as below:

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market is Segmented on the lines of Product Analysis, Application Analysis, End-User Analysis and Regional Analysis. By Product Analysis this market is segmented on the basis of BP monitoring devices, Pulmonary pressure monitoring devices and ICP monitoring devices. By Application Analysis this market is segmented on the basis of Treating neurodegenerative, Autoimmune, Cardiovascular disorders skin transplant, Oncology and Other.

By End-User Analysis this market is segmented on the basis of Hospitals Sector, ASCs Sector and Others Sectors. By Regional Analysis this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World.

This report provides:

1) An overview of the global market for Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market and related technologies. 2) Analyses of global market trends, with data from 2015, estimates for 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2024. 3) Identifications of new market opportunities and targeted promotional plans for using topical acne treatment Market. 4) Discussion of research and development, and the demand for new products and new applications. 5) Comprehensive company profiles of major players in the industry.

Request Sample Report from here: https://www.marketresearchengine.com/autologous-stem-cell-and-non-stem-cell-based-therapies-market

Table of Contents

1 INTRODUCTION

2 EXECUTIVE SUMMARY

3 AUTOLOGOUS STEM CELL & NON STEM SELL THERAPY -TECHNOLOGY LANDSCAPE ANALYSIS

4 AUTOLOGOUS STEM CELL & NON STEM SELL THERAPY TECHNOLOGY INVESTMENT POTENTIAL

4.1 INVESTMENT CLIMATE ASSESSMENT 4.1.1 INVESTOR NETWORKS 4.1.1.1 PUBLIC FUNDING BODIES 4.1.1.2 FUNDING/GRANTS FROM NGO ORGANIZATIONS 4.1.1.3 PRIVATE INVESTORS AND VENTURE CAPITAL FIRMS 4.1.1.4 INSIGHTS ON CURRENT AND FUTURE TECH-INVESTMENT TRENDS 4.1.1.5 INVESTOR INCLINATION AND PATTERNS 4.2 INVESTMENT OPPURTUNITIES 4.2.1 LICENSING AND ACQUISITION 4.2.2 ANALYSIS OF POTENTIAL APPLICATION AREAS FOR TECHNOLOGY INVESTMENT

5 AUTOLOGOUS STEM CELL MARKET LANDSCAPE ANALYSIS

6 AUTOLOGOUS STEM CELL & NON STEM SELL THERAPY TECHNOLOGY ADOPTION POTENTIAL AND DEVELOPMENT BY GEOGRAPHY

7 COMPETITIVE LANDSCAPE

8 PATENT ANALYSIS

9 TECHNOLOGY ANALYSIS AND ROAD MAPPING

10 ANALYST INSIGHTS AND RECOMMENDATIONS

11 COMPANY PROFILES

11.1 ANTRIA (CRO) (U.S.)

11.2 BIOHEART (U.S.)

11.3 BRAINSTORM CELL THERAPEUTICS (U.S.)

11.4 CYTORI (U.S.)

11.5 DENDREON CORPORATION (U.S.)

11.6 FIBROCELL (U.S.)

11.7 GENESIS BIOPHARMA (U.S.)

11.8 GEORGIA HEALTH SCIENCES UNIVERSITY (U.S.)

11.9 NEOSTEM (U.S.)

11.10 OPEXA THERAPEUTICS (U.S.)

11.11 ORGENESIS (U.S.)

11.12 REGENEXX (U.S.)

11.13 REGENEUS (AUSTRALIA)

11.14 TENGION (U.S.)

11.15 TIGENIX (BELGIUM)

11.16 VIRXSYS (U.S.)

Other Related Market Research Reports:

Asia-Pacific Chromatography Solvents Market is Forecast to Cross US$ 555. 5 Million By 2024

Antidiabetics Market is Projected to Reach USD 80.0 Billion By 2024

Antibacterial Drugs Market is Projected to Reach US$ 38 Billion By 2023

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

The rest is here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Development Trends & Competitive Analysis by Leading Industry Players - The...

Global Adipose Derived Stem Cell Therapy Market 2020 Industry Analysis, Growth Factors, Share, Opportunities and Forecast to 2025 – The Daily…

Global Adipose Derived Stem Cell Therapy Market 2020 by Company, Type and Application, Forecast to 2025 is the latest addition to the database of MarketsandResearch.biz which exhibits an easily comprehensible description of the global market. The report provides proficient and in-depth research on the market, focusing on the market landscape and its growth prospects over the coming years from 2020 to 2025. The report emphasizes market share, market demographics, size as well as valuation and voluminous growth rate. The research also includes a discussion of the key vendors operating in this global Adipose Derived Stem Cell Therapy market. The study shares details such as current trends of the market in conjunction with the geographical landscape, demand scope, remuneration scale, and growth graph of this vertical have also been included in this report.

The report covers an in-depth analysis of the key trends and emerging drivers of the market as well as market characteristics, competitive landscape, market size and growth, regional breakdown, and strategies for this market. The research analyzes revenue growth, product range, and pricing factors related to the global Adipose Derived Stem Cell Therapy market. The report sheds light on the competition matrix and shares a versatile understanding of various vital details comprising new product related developments that are adequately addressed and invested by leading players in the global market. Details about the competitive landscape, ensuring robust growth in the global market has been given in the report.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/89396

The major players covered in the market are: AlloCure, Mesoblast, Cellleris, Antria, Intrexon, Celgene Corporation, Tissue Genesis, Cytori Therapeutics, Corestem, Pluristem Therapeutics, Cyagen, BioRestorative Therapies, Lonza, Pluristem Therapeutics, Celltex Therapeutics Corporation, iXCells Biotechnologies

Scope of Market Report:

This report provides an analysis of the supply chain, import, and export control, and future influence on the industry. Detailed analysis of the market status, competition pattern, advantages, and disadvantages of enterprise products, industry development trends (2020-2025), regional industrial layout characteristics, industrial policy has also been included. From raw materials to end-users of this industry are analyzed, as well as the trends of product circulation and sales channels are presented.

On the basis of regional segmentation, the market is bifurcated into major regions of North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, etc.), Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa). The regional analysis further covers country-wise bifurcation of the market and key players.

On the basis of product type, we research the production, revenue, price, market share, and growth rate, primarily split into: Autologous Stem Cells, Allogeneic Stem Cells

For the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Adipose Derived Stem Cell Therapy market report for each application, including: Therapeutic Application, Research Application

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/89396/global-adipose-derived-stem-cell-therapy-market-2020-by-company-type-and-application-forecast-to-2025

Unraveling Report Offerings

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact Us Mark Stone Head of Business Development Phone: +1-201-465-4211 Email: [emailprotected] Web: http://www.marketsandresearch.biz

Read the original post:
Global Adipose Derived Stem Cell Therapy Market 2020 Industry Analysis, Growth Factors, Share, Opportunities and Forecast to 2025 - The Daily...

STEM CELL BANKING Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 – The Daily Chronicle

Fort Collins, Colorado The STEM CELL BANKING Market is growing at a rapid pace and contributes significantly to the global economy in terms of turnover, growth rate, sales, market share and size. The STEM CELL BANKING Market Report is a comprehensive research paper that provides readers with valuable information to understand the basics of the STEM CELL BANKING Report. The report describes business strategies, market needs, dominant market players and a futuristic view of the market.

The report has been updated to reflect the most recent economic scenario and market size regarding the ongoing COVID-19 pandemic. The report looks at the growth outlook as well as current and futuristic earnings expectations in a post-COVID scenario. The report also covers changing market trends and dynamics as a result of the pandemic and provides an accurate analysis of the impact of the crisis on the market as a whole.

Global STEM CELL BANKING Market to reach USD 11.2 billion by 2025. Global STEM CELL BANKING Market valued approximately USD 5.4 billion in 2016 is anticipated to grow with a healthy growth rate of more than 8.4% over the forecast period 2017-2025.

Get a sample of the report @ https://reportsglobe.com/download-sample/?rid=5214

Industry STEM CELL BANKING Study provides an in-depth analysis of key market drivers, opportunities, challenges and their impact on market performance. The report also highlights technological advancements and product developments that drive market needs.

The report contains a detailed analysis of the major players in the market, as well as their business overview, expansion plans and strategies. Key players explored in the report include:

The report provides comprehensive analysis in an organized manner in the form of tables, graphs, charts, pictures and diagrams. Organized data paves the way for research and exploration of current and future market outlooks.

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=5214

The report provides comprehensive data on the STEM CELL BANKING market and its trends to help the reader formulate solutions to accelerate business growth. The report provides a comprehensive overview of the economic scenario of the market, as well as its benefits and limitations.

The STEM CELL BANKING Market Report includes production chain analysis and value chain analysis to provide a comprehensive picture of the STEM CELL BANKING market. The research consists of market analysis and detailed analysis of application segments, product types, market size, growth rates, and current and emerging industry trends.

By Application:

Request customization of the report @https://reportsglobe.com/need-customization/?rid=5214

The market is geographically spread across several key geographic regions and the report includes regional analysis as well as production, consumption, revenue and market share in these regions for the 2020-2027 forecast period. Regions include North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

Radical Coverage of the STEM CELL BANKING Market:

Key Questions Addressed in the Report:

To learn more about the report, visit @ https://reportsglobe.com/product/global-stem-cell-banking-market-size-study/

Thanks for reading our report. It is possible to adapt this report to the wishes of the customer. Contact us to learn more about the report and our team will make sure you create a report based on your needs.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

See the rest here:
STEM CELL BANKING Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 - The Daily Chronicle

EV Biologics To Perform Specialized Analysis of EV Biopharmaceuticals at Vanderbilt University – BioSpace

CHEYENNE, WY / ACCESSWIRE / September 29, 2020 / EV Biologics, Inc. formerly Yulong Eco-Materials Limited (OTC PINK:YECO) today announced that it intends to utilize the advanced instrumentation and research staff at the Vanderbilt Institute of Nanoscale Science and Engineering (VINSE) and the Vanderbilt Center for Structural Biology (CSB) in the development of extracellular vesicle (EV)-based diagnostics and therapeutics.

Founded in 1873, Vanderbilt University located in Nashville, Tennessee is a pre-eminent and legendary private research university comprised of 10 distinct schools and colleges on one centralized campus. Regularly ranked as one of the nation's top 15 universities by publications such as "U.S. News & World Report", with programs that rank in the top 10, Vanderbilt is a world-class institution. The University was recently ranked #10 in Reuter's assessment of the World's Most Innovative Universities. (Source: Vanderbilt University Website - https://www.vanderbilt.edu/csb).

Quality Control (QA/QC) is the cornerstone of the Company's plan for Current Good Manufacturing Practices cGMP development of EV diagnostics and therapeutic products. The Vanderbilt CSB and VINSE are extraordinary research facilities that have the capability of performing nanoscale analytical methods such as Atomic Force Microscopy, Electron Microscopy and Nano Tracking Analysis. The Vanderbilt University research staff has extensive experience with nanoparticle characterization methods that will form an essential part of QA/QC for the Company's therapeutic development.

The Company is making a significant investment in its own analytical equipment to facilitate novel solutions to overcome the challenges in EV product characterization and standardization. EV analysis performed by research staff at Vanderbilt will complement and confirm the Company's own EV development data and will provide the orthogonal characterization for EV research recommended by the International Society for Extracellular Vesicles.

CMO, Dr. Jason Sanders, said "having access to this kind of extremely specialized instrumentation and experts in nanoparticle analysis at such a highly respected institution as Vanderbilt will be instrumental in advancing our R&D program for biopharmaceuticals and will enable meticulous analysis for preparation of Investigational New Drug applications (IND's) to the FDA for maximum efficiency in EV drug development."

The Company is currently in the process of getting a new trading symbol with FINRA after successfully getting our name changed. Our goal is to become current in our OTC filings by the end of October with OTC Markets

About the Company

EV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, intent on bringing human mesenchymal "MSC" and other stem cell and cell-derived products to market in the cosmetic and biopharmaceutical spaces. Initially, these novel and unique products will be specifically provided to the international clinical research community including universities and physicians and will be targeted to the aesthetic and regenerative medicine markets. Using proprietary and patentable technologies, the Company is creating exclusive IP and IT inherent in our superior products. Further product development will be focused on investigation of novel stem cell-derived biopharmaceuticals designed for specific clinical conditions.

Forward-Looking Statements

This press release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company's financial position and business strategy. The words or phrases "plans," "would be," "will allow," "intends to," "may result," "are expected to," "will continue," "anticipates," "expects," "estimate," "project," "indicate," "could," "potentially," "should," "believe," "think," "considers" or similar expressions are intended to identify "forward-looking statements." These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

YECO has 6.21 million shares issued and outstanding with a float of 1,016,375 shares.

Contact:

Dennis Burns Investor Relations Tel(567)237-4132 dburns@nvestrain.com

For more information on EV Biologics please visit: http://www.evbiologics.com

SOURCE: Yulong Eco-Materials Limited

View source version on accesswire.com: https://www.accesswire.com/608226/EV-Biologics-To-Perform-Specialized-Analysis-of-EV-Biopharmaceuticals-at-Vanderbilt-University

Go here to read the rest:
EV Biologics To Perform Specialized Analysis of EV Biopharmaceuticals at Vanderbilt University - BioSpace

JAMA Oncology Highlights Plinabulin’s Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy – GlobeNewswire

September 29, 2020 08:00 ET | Source: BeyondSpring, Inc.

NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the Company or BeyondSpring) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology therapies to transform the lives of patients with unmet medical needs, today announced that the Companys manuscript, titled Efficacy of Plinabulin vs. Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer, has been published in JAMA Oncology, the American Medical Associations peer-reviewed journal.

The manuscript analyzed BeyondSprings Phase 2 portion of its PROTECTIVE-1 (Study 105) randomized clinical trial, which consisted of four treatment arms and was conducted in 19 treatment centers in the U.S., China, Russia and Ukraine from April 2017 through March 2018, with Covance serving as its contract research organization. Key primary and secondary endpoints were calculated using objective data, such as the absolute neutrophil count and platelet counts, which were based on validated assays conducted at Covances central labs in three continents. Participants were adult patients with non-small cell lung cancer (NSCLC) whose cancer had progressed after platinum-based chemotherapy. The objective was to assess the efficacy and safety of the Companys lead asset, Plinabulin, compared with Pegfilgrastim, a long-lasting G-CSF, which is currently the predominant therapy for chemotherapy-induced neutropenia (CIN) prevention.

The protocols were as follows:

Key results included:

The data presented demonstrates that Plinabulin a novel, non-G-CSF small molecule with anticancer activity has potent neutropenia prevention effects, said Dr. Douglas Blayney, Principal Investigator of BeyondSprings CIN program with Plinabulin. The results show the promise that Plinabulin has to deliver relief to cancer patients suffering around the world.

The results of this study validate Plinabulins strength and its potent ability to prevent CIN in cancer patients, added Dr. Ramon Mohanlal, BeyondSprings Chief Medical Officer and Executive Vice President, Research and Development. This study, coupled with the breakthrough designation granted to our CIN program from boththeU.S. FDAand China NMPA,is highly encouraging for our pending New Drug Application filings in bothcountries.

To access the full e-publication, please visit: https://jamanetwork.com/journals/jamaoncology/article-abstract/2770700.

About BeyondSpring Headquartered in New York, BeyondSpring is a global, clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to improve clinical outcomes for patients with high unmet medical needs. BeyondSprings first-in-class lead immune asset, Plinabulin, is a potent antigen-presenting cell (APC) inducer. It is currently in two Phase 3 clinical trials for two severely unmet medical needs indications: one is for the prevention of chemotherapy-induced neutropenia (CIN), the most frequent cause for a chemotherapy regimen doses decrease, delay, downgrade or discontinuation, which can lead to suboptimal clinical outcomes. The other is for non-small cell lung cancer (NSCLC) treatment in EGFR wild-type patients. As a pipeline drug, Plinabulin is in various I/O combination studies to boost PD-1 / PD-L1 antibody anti-cancer effects. In addition to Plinabulin, BeyondSprings extensive pipeline includes three pre-clinical immuno-oncology assets and a drug discovery platform dubbed molecular glue that uses the protein degradation pathway.

About Plinabulin Plinabulin, BeyondSprings lead asset, is a differentiated immune and stem cell modulator. Plinabulin is currently in late-stage clinical development to increase overall survival in cancer patients, as well as to alleviate chemotherapy-induced neutropenia (CIN). The durable anticancer benefits of Plinabulin have been associated with its effect as a potent antigen-presenting cell (APC) inducer (through dendritic cell maturation) and T-cell activation (Chem and Cell Reports, 2019). Plinabulins CIN data highlights the ability to boost the number of hematopoietic stem / progenitor cells (HSPCs), or lineage-/cKit+/Sca1+ (LSK) cells in mice. Effects on HSPCs could explain the ability of Plinabulin to not only treat CIN but also to reduce chemotherapy-induced thrombocytopenia and increase circulating CD34+ cells in patients.

Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company's future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSprings most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Media Contacts Caitlin Kasunich / Raquel Cona KCSA Strategic Communications ckasunich@kcsa.com / rcona@kcsa.com

Read the rest here:
JAMA Oncology Highlights Plinabulin's Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy - GlobeNewswire

Research Report and Overview on Stem Cell Cryopreservation Equipments Market, 2020-2027 with , Chart, Worthington Industries, Cesca Therapeutics,…

(September 2020):WMRsLatest Study on Stem Cell Cryopreservation Equipments Market report 2020-2027 providesan Overview of the current market situation,competitive analysis, product scope, market research, opportunities, driving force, and market risks. The report contains market forecast to 2027 related to market size, Consumption, gross margin, price,revenue, production, CAGR and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.

The Stem Cell Cryopreservation Equipments market report provides a basic overview of the industry, including definitions, classifications, applications, and chain structures. Stem Cell Cryopreservation Equipments market analysis is provided to international markets, including development trends, competitive environment analysis, and key regions development status.

Get the FREE Report Sample (Includes- Keyplayers Profiles, Table and Figures, ToC):https://www.worldwidemarketreports.com/sample/299689

Stem Cell Cryopreservation Equipments Market Segments Analysis Covers;

The major manufacturers covered in this report: , Chart, Worthington Industries, Cesca Therapeutics, Shengjie Cryogenic Equipment, Sichuan Mountain Vertical, Qingdao Beol,

Considering keyword Market factors, Types Covers: Liquid Phase, Vapor Phase,

Application Covers: Cord Blood Stem Cell Cryopreservation, Other Stem Cell Cryopreservation

Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; emergency declared in many countries; massive slowing of the supply chain; stock market unpredictability; falling business assurance, growing panic among the population, and uncertainty about future.

COVID-19 can affect the global Stem Cell Cryopreservation Equipments economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Get the Free Analysis on Coivd-19with Report, here you can ask for the Structured Report:https://www.worldwidemarketreports.com/covidimpact/299689

Table of Content (TOC) of Stem Cell Cryopreservation Equipments Market 2020:Chapter 1 Introduction and Overview Chapter 2 Industry Cost Structure and Economic Impact Chapter 3 Rising Trends and New Technologies with Major key players Chapter 4 Global Stem Cell Cryopreservation Equipments Market Analysis, Trends, Growth Factor Chapter 5 Stem Cell Cryopreservation Equipments Market Application and Business with Potential Analysis Chapter 6 Global Stem Cell Cryopreservation Equipments Market Segment, Type, Application Chapter 7 Global Stem Cell Cryopreservation Equipments Market Analysis (by Application, Type, End-User) Chapter 8 Major Key Vendors Analysis of Stem Cell Cryopreservation Equipments Market Chapter 9 Development Trend of Analysis Chapter 10 Covid-19 Analysis Chapter 10 Conclusion

Any quiry or Customization in ToC, place hre:https://www.worldwidemarketreports.com/quiry/299689

Benefits of buying Overbed Table Market Report:

Else, Contact Us:

Mr. Shah Worldwide Market Reports Seattle, WA 98154, U.S. Email: [emailprotected]

Here is the original post:
Research Report and Overview on Stem Cell Cryopreservation Equipments Market, 2020-2027 with , Chart, Worthington Industries, Cesca Therapeutics,...

Singapore inks research collaboration with India for biotherapeutics – BSA bureau

Manipal Academy of Higher Education (MAHE) in India and Esco Aster in Singapore have signed agreement to establish collaborative research unit at MAHE, Manipal

This is the second Esco Aster collaborative research unit set up globally after the firstCentre of Excellence (COE) with Bioprocessing Technology Institute (BTI), Singapore. Esco Aster hopes to continue to develop more collaborations in Asia Pacific in years to come to work on the booming cell and gene therapy.

As per the agreement, ESCO Aster and MAHE will jointly establish a research unit at MAHE Manipal campus to carry outactivities related to development and manufacturing in the biotherapeutics area.MAHE will provide cGMP compliant facility and necessary resources for carrying out the research activities.

-Lt. General Dr. Venkatesh M.D., MAHEs Vice Chancellor

Weare excited to sign this agreement with MAHE and we look forward for harnessing the skilled manpower and mentor pool available at MAHE to build our pipeline products and services to our clients. We envision showcasing this research unit to our potential clients and collaborators and also utilizing it as a training centre.

-Xiangliang Lin, Esco Aster Chief Executive Officer

Through this agreement, both parties aim to facilitate research, development, and commercial plans and activities relating to stem cells or extracellular vesicles. Other fields of study with potential advantages to scientific discoveries are also welcome. This collaboration opens up potential breakthrough discoveries aiming to drive the biotherapeutics industry.

Read this article:
Singapore inks research collaboration with India for biotherapeutics - BSA bureau